For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd8206Oa&default-theme=true
RNS Number : 8206O Indivior PLC 30 June 2025
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
Richmond, VA, June 30, 2025 - Indivior PLC (Nasdaq / LSE: INDV) will be added
as a member of the U.S. small-cap Russell 2000® Index, effective after the
U.S. market opens today as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell U.S. indexes captures the 4,000
largest U.S. stocks as of April 30, ranking them by total market
capitalization. Membership in the Russell 2000® Index, which remains in place
for one year, is based on membership in the broad-market Russell 3000® Index.
The stock also was automatically added to the appropriate growth and value
indexes.
"Indivior's inclusion in the U.S. Russell indexes further aligns our capital
markets presence with our growing U.S. business profile. In 2024, 85% of our
net revenue was generated in the U.S. predominately from SUBLOCADE®, our
first-in-class, long-acting injectable medication for the treatment of opioid
use disorder. We are committed to building our U.S. presence and increasing
value for our stakeholders," said Joe Ciaffoni, Chief Executive Officer of
Indivior.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment strategies.
According to data as of the end of June 2024, about $10.6 trillion in assets
are benchmarked against the U.S. Russell indexes, which belong to FTSE
Russell, the global index provider.
For more information on the Russell 2000® and 3000® indexes and the Russell
indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE
Russell website (https://www.lseg.com/en/ftse-russell/russell-reconstitution)
.
About Indivior:
Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat opioid use disorder (OUD). Our vision
is that all patients around the world will have access to evidence-based
treatment for OUD and we are dedicated to transforming OUD from a global human
crisis to a recognized and treated chronic disease. Building on its global
portfolio of OUD treatments, Indivior has a pipeline of product candidates
designed to expand on its heritage in this category. Headquartered
in the United States in Richmond, VA, Indivior employs over 1,000
individuals globally and its portfolio of products is available in over 30
countries worldwide. Visit www.indivior.com (https://www.indivior.com/en)
to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://www.linkedin.com/company/indivior/?viewAsMember=true) .
About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking,
analytics and data solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset classes in
more than 70 countries, covering 98% of the investable market globally. FTSE
Russell index expertise and products are used extensively by institutional and
retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE
Russell indexes. Leading asset owners, asset managers, ETF providers and
investment banks choose FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index design and
management: a transparent rules-based methodology is informed by independent
committees of leading market participants. FTSE Russell is focused on applying
the highest industry standards in index design and governance and embraces the
IOSCO Principles. FTSE Russell is also focused on index innovation and
customer partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit FTSE Russell
(https://www.lseg.com/en/ftse-russell) .
# # #
Media Contacts:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Cassie.france-kelly@indivior.com (mailto:Cassie.france-kelly@indivior.com)
Investor Contacts:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123
jason.thompson@indivior.com (mailto:jason.thompson@indivior.com)
Tim Owens
Director, Investor Relations
Tel: 804-263-3978
timothy.owens@indivior.com (mailto:timothy.owens@indivior.com)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCPKOBKQBKDDAB